{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"4.9","value":"1.8"},{"comment":"The upper limit of the confidence interval was not estimable because too few participants had disease progression or died.","groupId":"OG001","lowerLimit":"1.4","upperLimit":"NA","value":"1.8"},{"groupId":"OG002","lowerLimit":"1.4","upperLimit":"7.5","value":"2.7"},{"groupId":"OG003","lowerLimit":"0.8","upperLimit":"2.1","value":"1.8"},{"groupId":"OG004","lowerLimit":"0.7","upperLimit":"5.4","value":"3.5"},{"groupId":"OG005","lowerLimit":"1.2","upperLimit":"1.8","value":"1.6"},{"groupId":"OG006","lowerLimit":"1.2","upperLimit":"15.7","value":"4.6"},{"groupId":"OG007","lowerLimit":"1.7","upperLimit":"5.1","value":"1.8"},{"groupId":"OG008","lowerLimit":"0.1","upperLimit":"9.9","value":"1.6"},{"groupId":"OG009","lowerLimit":"1.8","upperLimit":"6.7","value":"2.2"},{"groupId":"OG010","lowerLimit":"1.8","upperLimit":"15.5","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"6"}],"units":"Participants"}],"description":"PFS was defined as the length of time between the Baseline visit (Day 1) and the earlier of death or the first assessment of PD, as determined by investigator assessment of objective radiographic disease assessments per RECIST v1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 milligrams (mg) every 2 weeks (Q2W) beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as intravenous (IV) infusions.","id":"OG000","title":"Phase 1, Dose Escalation: INCAGN01949 70 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG001","title":"Phase 1, Dose Escalation: INCAGN01949 200 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG002","title":"Phase 1, Dose Escalation: INCAGN01949 350 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 700 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG003","title":"Phase 1, Dose Escalation: INCAGN01949 700 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kilogram (kg) every 6 weeks (Q6W) beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG004","title":"Phase 1, Dose Escalation: INCAGN01949 70 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG005","title":"Phase 1, Dose Escalation: INCAGN01949 200 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG006","title":"Phase 1, Dose Escalation: INCAGN01949 350 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 700 mg Q2W beginning on Cycle 1 Day 1, followed by ipilimumab 1 mg/kg Q6W beginning on Cycle 1 Day 1, administered as IV infusions.","id":"OG007","title":"Phase 1, Dose Escalation: INCAGN01949 700 mg + Ipilimumab 1 mg/kg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 70 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG008","title":"Phase 1, Safety Expansion: INCAGN01949 70 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 200 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG009","title":"Phase 1, Safety Expansion: INCAGN01949 200 mg + Nivolumab 240 mg"},{"description":"Participants with advanced or metastatic select solid tumors received INCAGN01949 350 mg Q2W beginning on Cycle 1 Day 1, followed by nivolumab 240 mg Q2W beginning on Cycle 3 Day 1, administered as IV infusions.","id":"OG010","title":"Phase 1, Safety Expansion: INCAGN01949 350 mg + Nivolumab 240 mg"}],"paramType":"MEDIAN","populationDescription":"FAS. Median survival time was estimated using the Kaplan-Meier method. The confidence interval was calculated using the method of Brookmeyer and Crowley. Only participants with events of disease progression or death were analyzed.","reportingStatus":"POSTED","timeFrame":"up to 15.6 months","title":"Phase 1: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"days"}